CARE-NETNCT07939113
Real-World Effectiveness of Cabozantinib in Advanced Neuroendocrine Tumors: A Retrospective Multicenter Study Using the GTE-RENATEN National Database
StatusNot Yet Recruiting
PhaseNot specified
SponsorHospices Civils de Lyon
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
To evaluate, in real-world clinical practice, the Disease Control Rate (DCR) achieved with cabozantinib among patients with advanced or metastatic well-differentiated NETs treated between January 2020 and August 2026.
Timeframe: Retrospective data between January 2020 and August 2026
Arms and interventions
Advanced Neuroendocrine Tumors treated by cabozantinib follow in ENDOCAN RENATEN network
Adults ≥18 years. Histologically confirmed, well-differentiated NET (G1-G3) or typical/atypical thoracic carcinoids Metastatic or unresectable disease. Cabozantinib initiated between January 2020 and August 2026
Sites
1 site in 1 country
- Hospices Civils de Lyon, Medical Oncology Department, Edouard Herriot HospitalLyon, France